Abstract: TH-PO1203
Clinical Insights on AKI in Children After Hematopoietic Stem Cell Transplantation
Session Information
- Pediatric Nephrology: CV Health, CKD, AKI, Dialysis, Transplantation, and Health Services Research
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Pediatric Nephrology
- 1800 Pediatric Nephrology
Authors
- Ehlayel, Abdulla, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alhuthil, Raghad Tariq, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alsaedi, Hawazen, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Kardesh, Mohammad Khaled, Alfaisal University, Riyadh, Riyadh Province, Saudi Arabia
- Attoun, Leen, Alfaisal University, Riyadh, Riyadh Province, Saudi Arabia
- Altamimi, Lamar Abdulrahman, Alfaisal University, Riyadh, Riyadh Province, Saudi Arabia
- Saadeh, Sermin, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
Background
AKI is a common complication after hematopoetic stem cell transplantation (HSCT), affecting 20-84% of pediatric recipents. Our primary aim is to assess the incidence of AKI within 100 days of HSCT
Methods
Retrospective study at King Faisal Specialist Hospital & Research Center. Pediatric patients (<14 years) who underwent HSCT between January 2011 and December 2022 were included. Peak serum creatinine within the first 100 days was compared to baseline. AKI definition and staging was based on KDIGO criteria
Results
A total of 1648 patients were included. AKI occurred in 88.9%; Stage 1: 32.8%, Stage 2: 36.7%, and Stage 3: 19.5%. Fifty patients required dialysis. Patients with AKI were significantly older than those without AKI. Patients with Stage 3 AKI were more likely to receive mismatched related donor transplants, allogeneic grafts, GVHD prophylaxis, and myeloablative conditioning
Conclusion
AKI remains a significant complication after HSCT with higher incidence noted in later time period
Table 1. Clinical Characteristics
| Characteristic | N (%) |
| Male | 917 (55.5) |
| Age in years, median (IQR) | 4 (1–9) |
| HSCT Period Early (2011–2016) Late (2017–2022) | 837 (50.6) 816 (49.4) |
| Underlying Disease Non-malignant Malignant | 1,191 (72.1) 462 (28.0) |
| Graft Type Allogeneic Autologous | 1,490 (90.1) 163 (9.9) |
| Stem Cell Source Bone marrow Cord blood Peripheral blood | 1,152 (69.7) 214 (13.0) 287 (17.4) |
| Conditioning Given Yes No | 1,514 (91.6) 139 (8.4) |
| GVHD Prophylaxis Yes No | 1,406 (85.1) 247 (14.9) |
Table 2. Demographics & Analysis by AKI Group
Cumulative Incidence of Stage 3 AKI